FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907707966> ?p ?o ?g. }

• W2907707966 abstract "Epistaxis (nosebleed) most commonly affects children and the elderly. The majority of episodes are managed at home with simple measures. In more severe cases medical intervention is required to either cauterise the bleeding vessel, or to pack the nose with various materials. Tranexamic acid is used in a number of clinical settings to stop bleeding by preventing clot breakdown (fibrinolysis). It may have a role in the management of epistaxis as an adjunct to standard treatments, reducing the need for further intervention.To determine the effects of tranexamic acid (oral, intravenous or topical) compared with placebo, no additional intervention or any other haemostatic agent in the management of patients with epistaxis.The Cochrane ENT Information Specialist searched the Cochrane ENT Register (via CRS Web); Central Register of Controlled Trials (CENTRAL) (via CRS Web); PubMed; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 29 October 2018.Randomised controlled trials (RCTs) of tranexamic acid (in addition to usual care) compared with usual care plus placebo, usual care alone or usual care plus any other haemostatic agent, to control epistaxis in adults or children.We used the standard methodological procedures expected by Cochrane. The primary outcomes were control of epistaxis: re-bleeding (as measured by the proportion of patients re-bleeding within a period of up to 10 days) and significant adverse effects (seizures, thromboembolic events). Secondary outcomes were control of epistaxis as measured by the time to stop initial bleeding (the proportion of patients whose bleeding is controlled within a period of up to 30 minutes); severity of re-bleeding (as measured by (a) the proportion of patients requiring any further intervention and (b) the proportion of patients requiring blood transfusion); length of hospital stay and other adverse effects. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics.We included six RCTs (692 participants). The overall risk of bias in the studies was low. Two studies assessed oral administration of tranexamic acid, given regularly over several days, and compared it to placebo. In the other four studies, a single application of topical tranexamic acid was compared with placebo (one study) and a combination of epinephrine and lidocaine or phenylephrine (three studies). All participants were adults.Tranexamic acid versus placeboFor our primary outcome, control of epistaxis: re-bleeding (proportion re-bleeding within 10 days), we were able to pool data from three studies. The pooled result demonstrated a benefit of tranexamic acid compared to placebo, the risk of re-bleeding reducing from 67% to 47% (risk ratio (RR) 0.71, 95% confidence interval (CI) 0.56 to 0.90; three studies; 225 participants; moderate-quality evidence).When we compared the effects of oral and topical tranexamic acid separately the risk of re-bleeding with oral tranexamic acid reduced from 69% to 49%, RR 0.73 (95% CI 0.55 to 0.96; two studies, 157 participants; moderate-quality evidence) and with topical tranexamic acid it reduced from 66% to 43%, RR 0.66 (95% CI 0.41 to 1.05; single study, 68 participants). We rated the quality of evidence provided by the single study as low, therefore it is uncertain whether topical tranexamic acid is effective in stopping bleeding in the 10-day period after a single application.No study specifically sought to identify and report our primary outcome: significant adverse effects (i.e. seizures, thromboembolic events).The secondary outcome time to stop initial bleeding (proportion with bleeding controlled within 30 minutes) was measured in one study using topical tranexamic acid and there was no evidence of a difference at 30 minutes (RR 0.79, 95% CI 0.56 to 1.11; 68 participants; low-quality evidence).No studies reported the proportion of patients requiring any further intervention (e.g. repacking, surgery, embolisation).One study of oral tranexamic acid reported the proportion of patients requiring blood transfusion and found no difference between groups: 5/45 (11%) versus 6/44 (14%) (RR 0.81, 95% CI 0.27 to 2.48; 89 participants; low-quality evidence).Two studies reported hospital length of stay. One study reported a significantly shorter stay in the oral tranexamic acid group (mean difference (MD) -1.60 days, 95% CI -2.49 to -0.71; 68 participants). The other study found no evidence of a difference between the groups.Tranexamic acid versus other haemostatic agentsWhen we pooled the data from three studies the proportion of patients whose bleeding stopped within 10 minutes was significantly higher in the topical tranexamic acid group compared to the group receiving another haemostatic agent (70% versus 30%: RR 2.35, 95% CI 1.90 to 2.92; 460 participants) (moderate-quality evidence).Adverse effects across all studiesFive studies recorded 'adverse effects' in a general way. None found any difference between the groups in the occurrence of minor adverse effects (e.g. mild nausea and diarrhoea, 'bad taste' of gel). In one study a patient developed a superficial thrombophlebitis of both legs following discharge, however it is not reported in which group this occurred. No other serious adverse effect was reported in any study.We found moderate-quality evidence that there is probably a reduction in the risk of re-bleeding with the use of either oral or topical tranexamic acid in addition to usual care in adult patients with epistaxis, compared to placebo with usual care. However, the quality of evidence relating solely to topical tranexamic acid was low (one study only), so we are uncertain whether or not topical tranexamic acid is effective in stopping bleeding in the 10-day period after a single application. We found moderate-quality evidence that topical tranexamic acid is probably better than other topical agents in stopping bleeding in the first 10 minutes.There have been only three RCTs on this subject since 1995. Since then there have been significant changes in nasal cauterisation and packing techniques (for example, techniques including nasal endoscopy and more invasive approaches such as endoscopic sphenopalatine artery ligation). New trials would inform us about the effectiveness of tranexamic acid in light of these developments." @default.
• W2907707966 created "2019-01-11" @default.
• W2907707966 creator A5035539364 @default.
• W2907707966 creator A5054069874 @default.
• W2907707966 creator A5067992434 @default.
• W2907707966 creator A5078077580 @default.
• W2907707966 date "2018-12-31" @default.
• W2907707966 modified "2023-10-16" @default.
• W2907707966 title "Tranexamic acid for patients with nasal haemorrhage (epistaxis)" @default.
• W2907707966 cites W1552695479 @default.
• W2907707966 cites W177261470 @default.
• W2907707966 cites W1976010699 @default.
• W2907707966 cites W1986837360 @default.
• W2907707966 cites W1987650180 @default.
• W2907707966 cites W2032614826 @default.
• W2907707966 cites W2036468563 @default.
• W2907707966 cites W2050332147 @default.
• W2907707966 cites W2056135409 @default.
• W2907707966 cites W2058865836 @default.
• W2907707966 cites W2078702160 @default.
• W2907707966 cites W2087073355 @default.
• W2907707966 cites W2107339086 @default.
• W2907707966 cites W2138839806 @default.
• W2907707966 cites W2140440057 @default.
• W2907707966 cites W2292123940 @default.
• W2907707966 cites W2335974150 @default.
• W2907707966 cites W2480095255 @default.
• W2907707966 cites W2508644031 @default.
• W2907707966 cites W2598049992 @default.
• W2907707966 cites W2599123742 @default.
• W2907707966 cites W2605806871 @default.
• W2907707966 cites W2761153591 @default.
• W2907707966 cites W2768018286 @default.
• W2907707966 cites W2768825548 @default.
• W2907707966 cites W2779444445 @default.
• W2907707966 cites W2783394929 @default.
• W2907707966 cites W2788019177 @default.
• W2907707966 cites W4237846914 @default.
• W2907707966 cites W4248141438 @default.
• W2907707966 cites W4321434225 @default.
• W2907707966 cites W2140912725 @default.
• W2907707966 cites W2605377207 @default.
• W2907707966 doi "https://doi.org/10.1002/14651858.cd004328.pub3" @default.
• W2907707966 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6517002" @default.
• W2907707966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30596479" @default.
• W2907707966 hasPublicationYear "2018" @default.
• W2907707966 type Work @default.
• W2907707966 sameAs 2907707966 @default.
• W2907707966 citedByCount "25" @default.
• W2907707966 countsByYear W29077079662019 @default.
• W2907707966 countsByYear W29077079662020 @default.
• W2907707966 countsByYear W29077079662021 @default.
• W2907707966 countsByYear W29077079662022 @default.
• W2907707966 countsByYear W29077079662023 @default.
• W2907707966 crossrefType "journal-article" @default.
• W2907707966 hasAuthorship W2907707966A5035539364 @default.
• W2907707966 hasAuthorship W2907707966A5054069874 @default.
• W2907707966 hasAuthorship W2907707966A5067992434 @default.
• W2907707966 hasAuthorship W2907707966A5078077580 @default.
• W2907707966 hasBestOaLocation W29077079662 @default.
• W2907707966 hasConcept C120665830 @default.
• W2907707966 hasConcept C121332964 @default.
• W2907707966 hasConcept C126322002 @default.
• W2907707966 hasConcept C141071460 @default.
• W2907707966 hasConcept C142724271 @default.
• W2907707966 hasConcept C168563851 @default.
• W2907707966 hasConcept C197934379 @default.
• W2907707966 hasConcept C204787440 @default.
• W2907707966 hasConcept C27081682 @default.
• W2907707966 hasConcept C2776478404 @default.
• W2907707966 hasConcept C2779637338 @default.
• W2907707966 hasConcept C2991743468 @default.
• W2907707966 hasConcept C42219234 @default.
• W2907707966 hasConcept C535046627 @default.
• W2907707966 hasConcept C61511704 @default.
• W2907707966 hasConcept C71924100 @default.
• W2907707966 hasConceptScore W2907707966C120665830 @default.
• W2907707966 hasConceptScore W2907707966C121332964 @default.
• W2907707966 hasConceptScore W2907707966C126322002 @default.
• W2907707966 hasConceptScore W2907707966C141071460 @default.
• W2907707966 hasConceptScore W2907707966C142724271 @default.
• W2907707966 hasConceptScore W2907707966C168563851 @default.
• W2907707966 hasConceptScore W2907707966C197934379 @default.
• W2907707966 hasConceptScore W2907707966C204787440 @default.
• W2907707966 hasConceptScore W2907707966C27081682 @default.
• W2907707966 hasConceptScore W2907707966C2776478404 @default.
• W2907707966 hasConceptScore W2907707966C2779637338 @default.
• W2907707966 hasConceptScore W2907707966C2991743468 @default.
• W2907707966 hasConceptScore W2907707966C42219234 @default.
• W2907707966 hasConceptScore W2907707966C535046627 @default.
• W2907707966 hasConceptScore W2907707966C61511704 @default.
• W2907707966 hasConceptScore W2907707966C71924100 @default.
• W2907707966 hasIssue "12" @default.
• W2907707966 hasLocation W29077079661 @default.
• W2907707966 hasLocation W29077079662 @default.
• W2907707966 hasLocation W29077079663 @default.
• W2907707966 hasLocation W29077079664 @default.
• W2907707966 hasLocation W29077079665 @default.
• W2907707966 hasOpenAccess W2907707966 @default.
• W2907707966 hasPrimaryLocation W29077079661 @default.

• next